Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
D 42.89 -2.43% -1.07
XENE closed down 2.43 percent on Monday, March 18, 2024, on 84 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -2.43%
Inside Day Range Contraction -2.43%
Oversold Stochastic Weakness -2.43%
Lower Bollinger Band Walk Weakness -1.79%
Lower Bollinger Band Touch Weakness -1.79%
Oversold Stochastic Weakness -1.79%
Inside Day Range Contraction -4.86%
Oversold Stochastic Weakness -4.86%
Doji - Bullish? Reversal -3.07%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 7 hours ago
Down 2 % about 8 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Fell Below Previous Day's Low about 13 hours ago
Down 1% about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenon Pharmaceuticals Inc. Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Organic Compounds Chemical Compounds Gene Therapy Cardiovascular Disease Knee Pharmaceutical Industries Analgesics Osteoarthritis Acne Lipoprotein Neuropathic Pain Teva Pharmaceutical Industries Treatment Of Osteoarthritis Treatment Of Cardiovascular Disease Alipogene Tiparvovec Erythromelalgia Glybera Lipase Lipoprotein Lipase Deficiency Postherpetic Neuralgia

Is XENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 50.99
52 Week Low 27.985
Average Volume 390,811
200-Day Moving Average 39.48
50-Day Moving Average 46.48
20-Day Moving Average 46.56
10-Day Moving Average 44.86
Average True Range 1.67
RSI (14) 32.89
ADX 21.27
+DI 15.95
-DI 21.33
Chandelier Exit (Long, 3 ATRs) 45.97
Chandelier Exit (Short, 3 ATRs) 47.84
Upper Bollinger Bands 50.67
Lower Bollinger Band 42.44
Percent B (%b) 0.05
BandWidth 17.67
MACD Line -0.88
MACD Signal Line -0.38
MACD Histogram -0.5062
Fundamentals Value
Market Cap 3.23 Billion
Num Shares 75.3 Million
EPS -2.66
Price-to-Earnings (P/E) Ratio -16.12
Price-to-Sales 181.44
Price-to-Book 5.92
PEG Ratio -0.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.22
Resistance 3 (R3) 45.45 44.91 44.83
Resistance 2 (R2) 44.91 44.32 44.79 44.70
Resistance 1 (R1) 43.90 43.95 43.63 43.67 44.57
Pivot Point 43.36 43.36 43.23 43.24 43.36
Support 1 (S1) 42.35 42.77 42.08 42.12 41.21
Support 2 (S2) 41.81 42.40 41.69 41.08
Support 3 (S3) 40.80 41.81 40.95
Support 4 (S4) 40.57